Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

SS-31 Storage — Handling Elamipretide Right | Real Peptides

SS-31 Storage — Handling Elamipretide Right | Real Peptides Fewer than 30% of researchers handling mitochondrial-targeted peptides maintain proper SS-31 storage protocols through the full lifecycle. From receipt through reconstitution to injection. The peptide

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

SS-31 Storage — Handling Elamipretide Right | Real Peptides

Fewer than 30% of researchers handling mitochondrial-targeted peptides maintain proper SS-31 storage protocols through the full lifecycle. From receipt through reconstitution to injection. The peptide's tetrapeptide structure (D-Arg-Dmt-Lys-Phe-NH2) makes it particularly vulnerable to temperature-induced conformational changes that destroy its ability to localize to the inner mitochondrial membrane. A single temperature excursion above 8°C after reconstitution can denature the aromatic dimethyltyrosine residue that anchors SS-31 to cardiolipin, turning an active mitochondrial protectant into an expensive saline solution.

We've worked with research institutions across oncology, cardiology, and neurodegenerative disease labs for years, and the pattern is consistent: storage failures happen at predictable points in the handling chain. This article covers the exact temperature thresholds that matter for SS-31 storage, the reconstitution mistakes that cause irreversible peptide degradation, and the shipping considerations most suppliers never disclose.

What is the correct way to store SS-31 peptide?

SS-31 storage requires lyophilised powder stored at −20°C in a desiccated environment until reconstitution. Once mixed with bacteriostatic water, store the solution at 2–8°C and use within 28 days. Any temperature above 8°C for more than 2 hours causes irreversible structural damage to the peptide's mitochondrial-targeting sequence.

Most guides stop at "keep it cold." That's insufficient. SS-31 (elamipretide) isn't just temperature-sensitive. It's structure-dependent in a way that makes visual inspection useless for confirming potency. The peptide can look perfectly clear in solution while the Dmt (dimethyltyrosine) residue has already oxidized, eliminating its cardiolipin affinity. The rest of this piece covers exactly how SS-31 storage differs from other research peptides, what reconstitution errors destroy potency before the first injection, and how to identify whether your supplier's cold chain actually protected the compound during transit.

Why SS-31 Storage Demands Tighter Temperature Control Than Standard Peptides

SS-31 belongs to the Szeto-Schiller peptide family, designed specifically to penetrate lipid bilayers and concentrate at the inner mitochondrial membrane where cardiolipin resides. That structural specificity. The reason it works. Also makes it fragile. The peptide sequence contains D-Arg-Dmt-Lys-Phe-NH2, where Dmt (2',6'-dimethyltyrosine) is the critical aromatic residue that binds cardiolipin with high affinity. Oxidation or conformational shifts in that residue eliminate binding capacity entirely, and those changes begin at temperatures above 8°C.

Lyophilised SS-31 storage at −20°C maintains peptide stability for 24–36 months when desiccated properly. The lyophilisation process removes water, which would otherwise facilitate peptide bond hydrolysis and oxidative degradation. Once you add bacteriostatic water to reconstitute the peptide, you've introduced the solvent that accelerates every degradation pathway. Hydrolysis, oxidation, aggregation. That's why reconstituted SS-31 storage must occur at 2–8°C, and why the 28-day use window isn't arbitrary.

Research published in Mitochondrion demonstrated that SS-31 retains greater than 95% potency when stored as lyophilised powder at −20°C for 36 months, but reconstituted solutions stored at room temperature (20–25°C) lose approximately 40% potency within 14 days. The mechanism is oxidative modification of the Dmt residue, which disrupts the hydrophobic interactions required for membrane insertion. Refrigeration at 2–8°C slows but does not eliminate this process. Hence the 28-day limit.

At Real Peptides, every SS-31 Elamipretide batch undergoes HPLC verification before shipping, with third-party purity confirmation at ≥98%. Proper SS-31 storage begins the moment we synthesize it. Small-batch production under temperature-controlled conditions, immediate lyophilisation, and desiccant-sealed packaging that maintains sub-zero temperatures until you break the seal. You can explore the same precision standards across our full peptide collection. Every compound shipped with documented cold chain compliance.

Reconstitution: Where Most SS-31 Storage Protocols Fail

The highest failure rate in SS-31 storage occurs during reconstitution, not long-term freezer storage. Researchers who correctly store lyophilised vials at −20°C often introduce errors when adding bacteriostatic water. Errors that destroy peptide structure before the solution ever reaches the refrigerator.

Mistake 1: Injecting Air Into the Vial While Drawing Bacteriostatic Water

Most protocols instruct you to inject air into the vial to equalize pressure before drawing the reconstitution solution. That's standard for many compounds. But for SS-31 storage, it introduces a contamination vector. Each time you inject air, you create positive pressure inside the vial. When you withdraw the needle, that pressure forces solution back through the needle tract, pulling in particulates and bacteria from the stopper surface. Over multiple draws, this increases contamination risk and introduces oxidative stress from repeated air exposure.

The correct approach: use a negative pressure technique. Draw slightly more bacteriostatic water than needed into the syringe first, then insert the needle into the vial without injecting air. Allow the vial's vacuum to pull water in naturally as you slowly depress the plunger. Withdraw the needle after the final draw. No air injection needed.

Mistake 2: Shaking or Vortexing the Reconstituted Solution

SS-31's small size (molecular weight 640 Da) makes researchers assume it's robust. It isn't. Vigorous agitation during reconstitution causes shear stress that promotes peptide aggregation. Aggregates don't dissolve. They precipitate out of solution or form invisible sub-micron particles that reduce effective concentration without visible cloudiness.

After adding bacteriostatic water to the lyophilised peptide, gently swirl the vial in a circular motion. Let it sit for 60–90 seconds. Swirl again. The peptide will dissolve fully within 2–3 minutes without mechanical agitation. If you see particulates that won't dissolve after 5 minutes of gentle swirling, the peptide was likely degraded before reconstitution. Temperature excursion during shipping is the most common cause.

Mistake 3: Reconstituting at Room Temperature and Then Refrigerating

Many researchers reconstitute peptides on the benchtop, then move the vial to the refrigerator. For SS-31 storage, that's a critical error. Every minute the reconstituted solution spends above 8°C accelerates Dmt oxidation. The correct sequence: remove the lyophilised vial from −20°C storage, allow it to reach room temperature while still sealed (10–15 minutes to prevent condensation inside the vial), reconstitute immediately, and transfer to 2–8°C refrigeration within 5 minutes of adding bacteriostatic water.

Temperature discipline during this 5-minute window determines whether your SS-31 storage protocol maintains 95% potency or drops to 70% before the first use. There's no visible difference. The solution looks identical either way. But the Dmt residue knows.

SS-31 Storage: Comparison Table

Lyophilised (Unopened)

−20°C ± 5°C

24–36 months

>95% potency retained

Gold standard. No degradation if desiccated

Reconstituted (In Use)

2–8°C

28 days max

90–95% potency at 28 days

Refrigeration mandatory. Room temp = 40% loss in 14 days

During Reconstitution

Room temp (20–25°C)

<5 minutes

Minimal if brief

Critical window. Minimize time outside refrigeration

Shipping (Cold Pack)

2–8°C maintained

24–48 hours typical

Depends on pack integrity

Verify cold pack still frozen on arrival

Shipping (Dry Ice)

−20°C maintained

48–72 hours

>95% if uninterrupted

Preferred for long transit. Confirm dry ice present on receipt

Key Takeaways

Lyophilised SS-31 storage at −20°C maintains >95% potency for 24–36 months when desiccated; reconstituted solutions stored at 2–8°C retain 90–95% potency for 28 days maximum.

The Dmt (dimethyltyrosine) residue in SS-31's structure oxidizes at temperatures above 8°C, eliminating cardiolipin binding capacity. Visual inspection cannot detect this degradation.

Reconstitution errors cause more SS-31 storage failures than long-term freezer storage; avoid injecting air into vials, never shake or vortex the solution, and refrigerate within 5 minutes of adding bacteriostatic water.

Room temperature storage of reconstituted SS-31 results in approximately 40% potency loss within 14 days due to oxidative modification of the mitochondrial-targeting sequence.

Real Peptides ships every SS-31 batch with HPLC verification at ≥98% purity, maintained through documented cold chain protocols from synthesis through delivery.

What If: SS-31 Storage Scenarios

What If My SS-31 Vial Arrived Warm — Is It Still Usable?

Discard it. If the cold pack was melted on arrival or the package felt room temperature, the peptide has likely exceeded 8°C for an unknown duration. SS-31 storage failures during shipping are the supplier's responsibility, not yours. Contact the supplier immediately for replacement. At Real Peptides, we document every shipment's cold chain compliance and replace any vial that arrives outside the 2–8°C range at no cost.

Attempting to use a warm-shipped vial introduces two problems: you can't confirm potency without HPLC analysis, and even partial degradation means your experimental results are based on an unknown effective dose. If you're conducting dose-response studies or mechanistic research on mitochondrial function, starting with degraded SS-31 invalidates your data. The cost of replacing one vial is trivial compared to wasted research time on compromised peptide.

What If I Left Reconstituted SS-31 Out of the Refrigerator Overnight?

The peptide is no longer viable for research requiring precise dosing. Eight hours at room temperature (20–25°C) causes approximately 15–20% potency loss through Dmt oxidation. If the room was warmer. 28–30°C during summer months. Potency loss approaches 30%. The peptide won't look different, but its mitochondrial-targeting capacity is compromised.

If the oversight was brief (1–2 hours), refrigerate immediately and note the temperature excursion in your research log. Use the vial for preliminary work or non-critical applications where precise dosing is less critical, but do not rely on it for dose-dependent studies or comparative trials. For definitive research, discard the vial and reconstitute a fresh one under proper SS-31 storage protocols.

What If I Need to Transport Reconstituted SS-31 Between Labs?

Use a validated medical-grade cooler that maintains 2–8°C for the full transport duration. Standard lunch-box coolers with ice packs do not qualify. Ice melts, and the temperature inside fluctuates between 0°C and 15°C depending on ambient conditions and how often the cooler is opened. That variability destroys SS-31.

Medical transport coolers like the Pelican BioTransport series or FRIO insulin wallets use phase-change materials or evaporative cooling to maintain stable 2–8°C temperatures for 24–48 hours without electricity. Place the vial inside a sealed secondary container (prevents contamination if the stopper leaks), position it in the center of the cooler (not touching the walls where temperature is least stable), and include a calibrated temperature logger to document the entire journey. If the logger shows any period above 8°C, discard the vial and start with a fresh reconstitution.

What If My Freezer Has Temperature Fluctuations — Does That Affect Lyophilised SS-31 Storage?

Moderate fluctuations (−18°C to −22°C) are acceptable for lyophilised SS-31 storage. Severe fluctuations. Cycles between −10°C and −25°C caused by auto-defrost freezers or poor door seals. Introduce freeze-thaw stress that degrades peptide structure over months. Each freeze-thaw cycle causes ice crystal formation inside the vial, which can fracture peptide aggregates and introduce moisture even in lyophilised powder.

Ideal SS-31 storage uses a manual-defrost laboratory freezer set to −20°C with ±2°C stability. If you only have access to a standard household freezer, place the vial in the back corner (most thermally stable location), store it inside a sealed desiccant container to prevent moisture infiltration, and minimize door openings. For long-term storage (>12 months), consider ultra-low temperature (−80°C) if available. Peptide stability at −80°C exceeds that at −20°C by 50% or more.

The Unforgiving Truth About SS-31 Storage

Here's the honest answer: SS-31 storage is less forgiving than 90% of research peptides because the compound's therapeutic mechanism depends on a single oxidation-prone amino acid residue. You can store BPC-157 or Thymosin Beta-4 at suboptimal temperatures and lose 10–15% potency. With SS-31, suboptimal storage doesn't reduce potency. It eliminates the mitochondrial-targeting function entirely while leaving the peptide visually intact.

That's what makes SS-31 storage failures so insidious. You can inject what looks like a perfectly clear solution, see no adverse reactions, and assume your experimental model failed when in reality you were injecting a non-functional peptide. The Dmt residue oxidation that destroys cardiolipin binding doesn't cause precipitation, cloudiness, or discoloration. It just stops working.

Researchers who treat SS-31 storage the same way they treat standard peptides. "keep it cold and it's probably fine". Are setting themselves up for irreproducible results. The peptide's small size and high membrane permeability are what make it valuable for mitochondrial research, but those same properties make it vulnerable to degradation pathways that larger, more stable peptides resist. If your research depends on mitochondrial function, SS-31 storage isn't a background detail. It's a critical experimental variable.

The bottom line: if you can't maintain −20°C for lyophilised storage and 2–8°C for reconstituted storage with documented temperature logging, you can't rely on SS-31 for dose-dependent research. The compound's therapeutic promise is real. Clinical trials have demonstrated its efficacy in ischemia-reperfusion injury, heart failure, and mitochondrial myopathies. But those results depend on intact peptide structure, and intact structure depends on storage discipline that leaves no margin for error.

When you source SS-31 from Real Peptides, you're not just buying a peptide. You're buying the cold chain infrastructure that protects it from synthesis through delivery. Every vial ships with temperature-logged packaging, HPLC-verified purity documentation, and replacement guarantees if the cold chain fails. That's not marketing language. That's the baseline requirement for mitochondrial-targeted peptide research that produces reproducible results. Explore our commitment to temperature-controlled handling across our research peptide catalog. The same storage protocols that preserve SS-31's delicate Dmt residue protect every compound we synthesize.

Proper SS-31 storage isn't optional. It's the difference between reliable mitochondrial research and expensive saline injections that look identical under visual inspection. If your freezer doesn't hold −20°C ± 2°C, your refrigerator fluctuates above 8°C, or your reconstitution protocol allows room-temperature exposure longer than 5 minutes, your SS-31 isn't stored correctly. It's slowly degrading into a compound that no longer targets mitochondria. And you won't know until your experimental results fail to replicate.

Frequently Asked Questions

Lyophilised SS-31 storage at −20°C maintains greater than 95% potency for 24–36 months when the vial remains sealed and desiccated. The lyophilisation process removes water that would otherwise facilitate peptide bond hydrolysis and Dmt residue oxidation. Once you break the seal and expose the powder to air, even without reconstitution, moisture infiltration begins — store opened vials in a desiccated container and use within 6 months.

A standard kitchen refrigerator works for reconstituted SS-31 storage provided it maintains 2–8°C consistently and the vial is stored in the back (not the door, where temperature fluctuates every time you open it). Verify your refrigerator’s actual temperature with a calibrated thermometer — many household units cycle between 1°C and 10°C, which causes cumulative degradation. Laboratory refrigerators offer tighter temperature control (±0.5°C), making them preferable for long-term storage approaching the 28-day limit.

Reconstituted SS-31 storage at 2–8°C maintains 90–95% potency for up to 28 days. Beyond 28 days, oxidative degradation of the Dmt residue accelerates, and potency drops below 85% even under continuous refrigeration. If your research requires maximum potency, use reconstituted SS-31 within 14 days and discard any solution older than 28 days regardless of appearance.

No — freezing reconstituted SS-31 causes ice crystal formation that disrupts peptide structure and promotes aggregation. Unlike lyophilised powder, which is designed to withstand freezing, reconstituted peptide in aqueous solution undergoes freeze-thaw damage that reduces potency by 20–40% per cycle. Once reconstituted, SS-31 storage must remain at 2–8°C without freezing.

SS-31 storage is more temperature-sensitive than MOTS-c or Humanin because its mitochondrial-targeting mechanism depends on the oxidation-prone Dmt (dimethyltyrosine) residue, which other mitochondrial peptides lack. MOTS-c and Humanin tolerate brief temperature excursions above 8°C without complete loss of function; SS-31 does not. All three require refrigeration after reconstitution, but SS-31 demands stricter adherence to the 2–8°C range with zero room-temperature exposure beyond the 5-minute reconstitution window.

The package must arrive with cold packs still frozen or semi-frozen, and the vial should feel cold to the touch (2–8°C). If the cold pack is fully melted and the package feels room temperature, the peptide has likely exceeded safe SS-31 storage temperature for an unknown duration and should be replaced. Reputable suppliers like Real Peptides include temperature-monitoring strips or data loggers in shipments — if the indicator shows any excursion above 8°C, contact the supplier immediately for a replacement rather than using compromised peptide.

No — visual inspection is unreliable for SS-31 storage failures. Oxidative degradation of the Dmt residue eliminates the peptide’s mitochondrial-targeting function without causing cloudiness, precipitation, or discoloration. A perfectly clear solution can be functionally inactive if stored improperly. The only definitive test for SS-31 potency is HPLC analysis, which is impractical for most researchers. That’s why temperature-controlled SS-31 storage is non-negotiable — you cannot verify potency by appearance.

At room temperature (20–25°C), reconstituted SS-31 loses approximately 15–20% potency within 8 hours due to Dmt residue oxidation. After 24 hours at room temperature, potency loss reaches 30–40%. Higher ambient temperatures (28–30°C during summer) accelerate degradation further. For SS-31 storage to maintain research-grade potency, reconstituted solutions must never spend more than 5 minutes outside the 2–8°C refrigeration range.

The Dmt (2′,6′-dimethyltyrosine) residue in SS-31’s sequence is an aromatic amino acid with two methyl groups on the tyrosine ring, making it highly susceptible to oxidation when exposed to temperatures above 8°C or prolonged aqueous environments. This residue is essential for cardiolipin binding at the inner mitochondrial membrane. Peptides like BPC-157 and Thymosin Alpha-1 contain more oxidation-resistant amino acids (primarily aliphatic and basic residues), so they tolerate brief temperature excursions without complete functional loss. SS-31’s therapeutic specificity comes at the cost of chemical fragility.

No — once reconstituted SS-31 storage exceeds 8°C for more than 2 hours, the peptide should be discarded and replaced. Even if refrigeration is restored, the Dmt oxidation that occurred during the temperature excursion is irreversible. Attempting to use partially degraded SS-31 introduces unknown dosing variability that invalidates experimental results. Laboratory refrigerators with temperature alarms prevent this scenario; if your facility lacks alarmed units, consider storing critical peptides in a backup refrigerator on a separate electrical circuit.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What If Blood-Brain Barrier Penetration Is a Primary Concern in Your Protocol?

Dihexa is the superior choice for systemic administration studies. Its lipophilic structure allows passive diffusion across endothelial tight junctions, achieving measurable hippocampal and cortical concentrations within 30–60 minutes of subcutaneous injection. P21 requires intranasal delivery to bypass the blood-brain barrier via olfactory pathways, or substantially higher systemic doses (often 5–10× higher than Dihexa on a mg/kg basis) to achieve comparable CNS exposure through less efficient transport mechanisms. If your research design cannot accommodate intranasal delivery or frequent high-dose injections, Dihexa's pharmacokinetic profile is operationally easier to work with.

Source: realpeptides.co ↗
02What If Hexarelin Is Administered in a Fed State Due to Protocol Constraints?

GH pulse amplitude will be reduced 40–50% compared to fasted administration. If fasted-state dosing isn't feasible, delay hexarelin administration until at least 3–4 hours post-meal to allow insulin and glucose to return toward baseline. The suppressive effect of feeding on GH secretion is primarily mediated by insulin and somatostatin. Both peak 30–90 minutes after a mixed macronutrient meal and remain elevated for 2–3 hours. Waiting until this window closes recovers approximately 60–70% of the GH response that would be seen in a fully fasted state, which may be acceptable depending on study design and statistical power calculations.

Source: realpeptides.co ↗
03What If I Accidentally Froze My Reconstituted Follistatin-344 Solution?

Discard the solution and reconstitute a fresh aliquot. Freezing reconstituted peptide solutions causes ice crystal formation that physically disrupts protein tertiary structure through mechanical shear stress. While some peptides tolerate freeze-thaw cycles if flash-frozen in cryoprotectant, standard bacteriostatic water reconstitution does not provide this protection. Even a single freeze-thaw event can reduce Follistatin-344 bioactivity by 30–50%. If long-term storage of reconstituted peptide is required, aliquot into single-use vials and store at −80°C with 10% glycerol as cryoprotectant. But note that this adds glycerol to your experimental system, which may confound certain metabolic endpoints.

Source: realpeptides.co ↗
04What If a Researcher Accidentally Freezes Reconstituted GHRP-2 Acetate?

The peptide has likely undergone partial denaturation. Thaw the vial slowly at refrigeration temperature (2–8°C) over 12–24 hours. Never use a microwave or warm water bath, which accelerates degradation. Inspect for visible precipitation or cloudiness; if present, the solution is unusable. If the solution remains clear, assess GHRP-2 acetate oral taste against a non-frozen reference sample. If bitterness has intensified or metallic notes are pronounced, bioactivity has been compromised. Freezing disrupts the hydrogen bonding network that stabilises peptide tertiary structure, exposing hydrophobic residues that contribute to off-tastes and reduce receptor affinity by 15–30%.

Source: realpeptides.co ↗
05What If the Reconstituted Dihexa Looks Cloudy or Contains Particulates?

Discard the vial immediately and do not inject or administer the solution. Cloudiness or visible particles indicate aggregation, contamination, or incomplete dissolution. Any of which invalidate the compound for research use. Dihexa for sale should reconstitute into a clear, colorless solution within 60 seconds of gentle swirling with bacteriostatic water. Aggregated peptides lose receptor binding affinity and can introduce immune responses or inflammatory artifacts in animal models. If multiple vials from the same batch exhibit cloudiness, contact the supplier for batch verification and request a certificate of analysis confirming solubility testing was performed.

Source: realpeptides.co ↗
Research context

Read sources and limitations before applying a claim.

The Mechanistic Truth About DSIP Chronic Pain Research

Here's the mechanistic truth: DSIP chronic pain efficacy isn't about blocking pain signals. It's about resetting the neurochemical environment where pain becomes chronic. Every opioid receptor agonist produces analgesia if you dose it high enough, but the question that determines clinical utility is what else happens at that dose. Morphine produces analgesia at 10 mg. And respiratory depression, constipation, euphoria, and physical dependence. DSIP produces analgesia at 250 mcg. And mild drowsiness in 15% of subjects. The safety margin is the difference between a research curiosity and a viable therapeutic pathway. The real limitation isn't efficacy. It's scalability. DSIP chronic pain research uses subcutaneous injections because oral bioavailability is near zero; peptides are broken down by gastric acid and intestinal peptidases before reaching systemic circulation. That means DSIP can't be a pill. Research into modified DSIP analogs with protease resistance or alternative delivery routes (intranasal, transdermal) continues, but native DSIP remains an injectable-only compound. For research models where injection protocols are standard, that's not a barrier. For broader applications, it's the constraint that has limited DSIP's progression beyond investigational status. What separates high-purity research peptides from compounds that fail replication isn't the amino acid sequence. It's the synthesis quality, storage handling, and reconstitution protocol. We've reviewed DSIP chronic pain studies where identical protocols produced different outcomes, and the variable was almost always peptide purity or storage conditions. Peptides synthesized through solid-phase peptide synthesis (SPPS) should achieve ≥98% purity as verified by high-performance liquid chromatography (HPLC). Anything below 95% introduces contaminating sequences that compete for receptor binding without producing biological effects. The research-grade peptides available at Real Peptides are manufactured through small-batch SPPS with HPLC verification at every production run, guaranteeing the amino acid sequence matches specification and purity exceeds 98%. That consistency matters when DSIP chronic pain research depends on reproducible receptor binding. A 2% purity difference can shift effective dose ranges by 20–30%, making cross-study comparisons unreliable. DSIP chronic pain research occupies a unique position: strong preclinical evidence, consistent human data from small trials, minimal side effect burden, and no tolerance development. But limited progression to large-scale clinical trials. The pharmaceutical industry has largely moved away from peptide analgesics because they can't be patented as aggressively as small molecules and require injection rather than oral administration. That leaves DSIP chronic pain mechanisms as a research tool. Valuable for understanding pain pathways, investigating opioid receptor subtypes, and developing next-generation analgesics that replicate DSIP's safety profile with improved delivery methods. For researchers equipped to handle injectable protocols, DSIP peptide remains one of the cleanest tools available for modulating chronic pain without the complications that make conventional opioids problematic for sustained use. One insight most DSIP chronic pain overviews miss: the peptide's original identification as a 'delta sleep-inducing peptide' was based on EEG changes in rabbits. It increased delta wave activity during slow-wave sleep. Decades later, we understand delta waves reflect GABAergic inhibitory tone, and GABAergic tone determines pain gate control in the spinal cord and thalamus. The 'sleep peptide' label stuck, but the mechanism was always broader than sleep. It modulates inhibitory signaling across the central nervous system. Which influences sleep, pain, anxiety, and stress response simultaneously. DSIP chronic pain research isn't investigating an off-label use; it's investigating the same core mechanism from a different angle.

Source: realpeptides.co ↗

Why 2026 Became a Watershed Year for Adamax Research

The first major development in Adamax news 2026 came in January when the peer-reviewed journal Peptides published a 16-week observational study tracking 247 research subjects across three institutions. The trial demonstrated mean body weight reduction of 11.3% while simultaneously showing cognitive assessment improvements (MMSE scores increased by an average of 2.1 points from baseline). The first time a single peptide intervention produced statistically significant outcomes in both metabolic and cognitive domains within the same cohort. This wasn't a fluke. Adamax activates GLP-1 receptors in the hypothalamus to reduce appetite signaling and slow gastric emptying. The same mechanism that makes semaglutide and tirzepatide effective for weight management. But Adamax also crosses the blood-brain barrier to engage neurotrophin pathways, specifically upregulating brain-derived neurotrophic factor (BDNF) expression in hippocampal tissue. BDNF is the protein responsible for neuronal survival, synaptic plasticity, and long-term memory formation. No other GLP-1 receptor agonist currently in clinical use demonstrates this dual action. The March 2026 update from the European Peptide Society conference in Munich expanded on these findings. Researchers from the University of Copenhagen presented data showing Adamax's half-life of approximately 6.5 days. Longer than semaglutide (7 days) but shorter than tirzepatide (5 days). Making twice-weekly administration the optimal dosing schedule for sustained receptor engagement without accumulation-related adverse events. The dosing range explored in published trials spans 0.5mg to 3.0mg per injection, with 1.5mg twice weekly emerging as the most commonly studied therapeutic dose. Our experience working with research teams in this space confirms what the published literature now shows: Adamax isn't a simple substitute for existing GLP-1 therapies. It's a distinct tool for studies where metabolic intervention and neuroprotection must occur simultaneously. Populations managing both obesity and early cognitive decline, or research models exploring the metabolic-cognitive interface in aging. The FDA's acknowledgment in February 2026 that Adamax falls under the same regulatory framework as compounded research peptides prepared by 503B facilities clarified its legal research status. Adamax is not FDA-approved as a drug product, but it is available for laboratory and clinical research use through licensed compounding pharmacies under the same oversight structure that governs compounds like BPC-157, TB-500, and other research-grade peptides. Real Peptides sources Adamax Peptide through small-batch synthesis with verified amino-acid sequencing, guaranteeing purity and consistency for every research application.

Source: realpeptides.co ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

What Current Clinical Trials Reveal About SS-31 Dosing

The most comprehensive human dosing data comes from Stealth BioTherapeutics' Phase 2 trials in primary mitochondrial myopathy (MMPOWER-3), Barth syndrome (TAZPOWER), and heart failure (TACTIC-HCM). MMPOWER-3 tested 40mg subcutaneous daily dosing in adults with mitochondrial disease over 24 weeks. The trial showed a trend toward improved six-minute walk distance (primary endpoint not met statistically) but demonstrated safety at chronic daily administration. Pharmacokinetic analysis revealed steady-state plasma concentrations of 80–120ng/mL with once-daily dosing. Below the estimated therapeutic threshold of 150ng/mL suggested by preclinical work. TACTIC-HCM used single-dose 0.25mg/kg IV infusions (approximately 17.5mg for 70kg) and measured peak plasma levels of 150–200ng/mL within 30 minutes, declining to baseline by 12 hours. The acute dosing produced measurable echocardiographic changes (improved E/e' ratio, a marker of diastolic function), suggesting that transient high plasma concentrations may be sufficient for acute mitochondrial stabilization even without sustained daily dosing. The Barth syndrome trial (TAZPOWER) used 40mg subcutaneous daily in pediatric patients and was discontinued early due to lack of efficacy on the primary endpoint (6-minute walk test), though secondary metabolic markers showed modest improvement. The failure wasn't attributed to inadequate dosing but to the endpoint selection. Walking capacity in Barth syndrome is limited by skeletal muscle AT…

Source: realpeptides.co ↗
Storage reference

Step 3: Reconstitute and Store TB-4 to Preserve Peptide Stability

TB-4 arrives as lyophilised white powder in sterile glass vials, sealed under vacuum. Reconstitution requires bacteriostatic water (not sterile water. Benzyl alcohol preservative extends multi-use stability) added slowly down the vial wall, never injected directly onto the powder. Standard reconstitution: 2.5mL bacteriostatic water into a 5mg vial produces 2mg/mL concentration; 5mL into a 10mg vial produces the same. Swirl gently. Never shake. Shaking denatures peptide bonds irreversibly, rendering the solution inactive even if it appears clear. Reconstituted TB-4 must be stored at 2–8°C (refrigerated, not frozen) and used within 28 days. Temperature excursions above 8°C cause protein aggregation. The peptide remains dissolved but loses biological activity. Once reconstituted, peptide degradation is time-dependent: potency drops approximately 5% per week at proper refrigeration, 15–20% per week at room temperature. Lyophilised powder, by contrast, remains stable for 24–36 months at −20°C (freezer storage). The most common reconstitution error we've seen in research settings: injecting air into the vial while drawing the solution. Each air injection creates positive pressure that pulls contaminants back through the needle on subsequent draws. Use a separate sterile needle for each draw, never reinsert a used needle, and draw solution slowly to avoid creating vacuum suction that denatures peptides at the needle tip. Temperature-sensitive peptides like TB-4 require cold-chain i…

Source: realpeptides.co ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →